Development of therapeutic applicationsProvision of a platform for joint development of therapeutic applicationsDevelopment and sale of clinical trial systems utilizing blockchainProvision of medical data analysis and consulting services using statistical analysis and machine learning
Entered into a capital and business alliance agreement with Suzuken Co., Ltd.
Entered into a capital and business alliance agreement with Sumitomo Corporation and Nippon Chemifa Corporation.
Entered into a capital and business alliance agreement with Sawai Pharmaceutical Co., Ltd.
Entered into a business alliance agreement with CMIC Inc. for the development support of digital therapeutics.
Approval for 'Monitoring Business Substitution Using Blockchain Technology' by the Ministry of Economy, Trade and Industry and the Ministry of Health, Labour and Welfare.
Started joint development of a treatment app for chronic kidney disease patients with Tohoku University and the Japan Kidney Rehabilitation Society.
Entered into a business alliance agreement with EPS Holdings Inc. to improve the efficiency of clinical trial operations using blockchain technology.
Head Office Relocation (10th Floor, Nihonbashi Honcho Showa Street Building, 3-7-2 Nihonbashi Honcho, Chuo-ku, Tokyo)
Relocated headquarters to 10th floor, Nihonbashi Honcho Showa-dori Building, 3-7-2 Nihonbashi Honcho, Chuo-ku, Tokyo
Achieved primary endpoints in domestic verification trial of insomnia disorder treatment app
Listed on Tokyo Stock Exchange Mothers Market
Entered into sales partnership agreement with Shionogi & Co., Ltd. regarding insomnia disorder treatment app
Transition from Mothers Market to Growth Market due to review of Tokyo Stock Exchange market classification
Initiated research and development on clinical data processing methods and quality assurance to promote data utilization with the National Center of Neurology and Psychiatry
Signed a business consignment agreement with Acuris Pharma Inc. for the world's first clinical trial using blockchain technology
Signed a contract with Kyorin Pharmaceutical Co., Ltd. for joint research, development, and sales of treatment apps in the otolaryngology field
Obtained manufacturing and marketing approval for insomnia disorder application
Signed a basic agreement with Tohoku University to promote the use of real-world data (RWD) of medical devices utilizing blockchain technology
Signed a contract with Asuka Pharmaceutical Co., Ltd. for joint research, development, and sales of treatment apps in the obstetrics and gynecology field
Approved as a designated research institution for scientific research grants by the Ministry of Education, Culture, Sports, Science and Technology
Transitioned to a company with an audit and supervisory committee
Obtained partial approval for manufacturing and sales of insomnia disorder app
Insurance coverage for insomnia disorder app approved
§07
News
17 ARTICLES
Web Seminar on Workplace Sleep Issues
On November 27, 2026, we will host a free web seminar featuring Professor Yuji Furuie, a special professor at the University of Tokyo, focusing on workplace sleep issues and solutions. Based on the latest data, we will explain the economic losses caused by sleep problems and health management measures with high return on investment. Target audience includes corporate health management, HR and labor personnel, health insurance association staff, occupational physicians, and public health nurses.
Interview with Taro Ueno Published in Nikkei Biotech
An article was published in Nikkei Biotech featuring an interview with Taro Ueno, President and CEO of Sasemed Co., Ltd., about the insomnia treatment app 'Medcle'. The article discusses the company's background in app development and its future outlook.
WIRED features interview with President Taro Ueno
An interview article featuring Taro Ueno, President and CEO of Sasemed Co., Ltd., was published in WIRED. The article discusses the company’s business and future prospects. Please see the link for details.
Sasemed Exhibits at Summit Held Concurrently with BioJapan 2026
Sasemed Co., Ltd. will exhibit at the "Japan Healthcare Venture Summit 2026", which is held concurrently with BioJapan 2026 at Pacifico Yokohama from October 7-9. Through the matching system, we will accept inquiries about clinical development efficiency support services and therapeutic apps, and will also exchange information at Booth V-09. We look forward to your visit.
Susmed's Insomnia App Medcle Featured in Yomiuri Shimbun
Susmed Inc.'s Medcle app for insomnia was featured in the Yomiuri Shimbun. See the linked article for details.
Publication of a dialogue article advertisement between Susmed and Asuka Pharmaceutical in Shareholder's Handbook
A dialogue article advertisement between Asuka Pharmaceutical Holdings and Susmed has been published in the investment magazine "Shareholder's Handbook." The publication date is September 16, 2026. Details of the article can be checked at the linked source.
World's First Announcement of Drug Manufacturing and Marketing Approval Obtained Using Blockchain Technology
Susmed Inc. announced that it has obtained the world's first drug manufacturing and marketing approval based on clinical trials conducted with the clinical trial system SUSMED SourceDataSync® utilizing blockchain technology. Details can be found in the company's press release.
SusMed President Taro Ueno Interviewed by Nikkei Medical
An interview with President Taro Ueno about Medcle, an app for insomnia disorder, was published in Nikkei Medical on September 4, 2026. See the linked page for details.
Susmed's Medcle Insomnia App Featured in Nikkei Medical
Susmed Inc.'s Medcle app for insomnia was featured in Nikkei Medical. See the linked article for details.
Sumased's Insomnia Disorder App Medcle Featured on NHK
On July 23, 2026, NHK NEWS Ohayō Nippon aired a segment featuring Sumased's insomnia disorder app Medcle. It was covered as part of digital healthcare, and details can be confirmed on the official website.
§08
Public records
GOV
National Tax Agency basic information7010003022232
Source: National Tax Agency Corporate Number Publication Site, basic three items
Trade name
サスメド株式会社
Trade name (kana)
サスメド
Name in English
SUSMED, Inc.
Corporation type
301
Address
〒103-0023 東京都中央区日本橋本町3丁目7番2号
Postal code
1030023
Prefecture code
13
City code
102
Address outside Japan
Prefecture in English
Tokyo
City in English
3-7-2, Nihonbashi-Honcho, Chuo ku
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2024-10-23
Change date
2021-10-21
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
1
Trade name image ID
Address image ID
Sequence number
2181940
METI gBizINFO7010003022232
Source: gBizINFO (Ministry of Economy, Trade and Industry)